Open AccessEvaluation of 500- and 1,000-mg doses of ciprofloxacin for the treatment of chancroid
Author(s) -
L Bodhidatta,
David N. Taylor,
Anupong Chitwarakorn,
Krit Kuvat,
Peter Echeverria
Publication year - 1988
Publication title -
antimicrobial agents and chemotherapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.07
H-Index - 259
eISSN - 1070-6283
pISSN - 0066-4804
DOI - 10.1128/aac.32.5.723
Subject(s) - chancroid , haemophilus ducreyi , ciprofloxacin , medicine , adverse effect , gastroenterology , pasteurellaceae , microbiology and biotechnology , antibiotics , immunology , biology , haemophilus influenzae , human immunodeficiency virus (hiv) , syphilis
A randomized, double-blind study was performed comparing ciprofloxacin in a 500-mg single dose with 1,000 mg (500-mg doses given 12 h apart) for the treatment of chancroid in Thailand. Haemophilus ducreyi was isolated from 87 (48%) of 180 men with a clinical diagnosis of chancroid. For men with ulcers that were culture positive for H. ducreyi, rates of cure were 100% in the 500-mg group and 98% in the 1,000-mg group. For men with ulcers that were culture negative for H. ducreyi, rates of cure were 93% in the 500-mg group and 96% in the 1,000-mg group. The MIC of ciprofloxacin for 50% of isolates among 85 isolates of H. ducreyi was 0.007 micrograms/ml (range, 0.002 to 0.03 micrograms/ml). No significant adverse effects were detected in either group. These data indicate that both of these treatment regimens are equally effective therapies for chancroid in Thailand.